ArticleFrontiers in microbiology2016
Bacteriophages as Potential Treatment for Urinary Tract Infections.
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Understanding bacterial biofilms: From definition to treatment strategies.Frontiers in cellular and infection microbiology · 2023Pooled it
- Trial
- Article
- Zinc oxide-bacteriophage synergistic combination for dual-mode antibacterial activity against multidrug-resistant Escherichia coli.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Therapeutic strategies for multi-resistantJAC-antimicrobial resistance · 2026Review
- Characterization of broad-host-range bacteriophages targeting multidrug-resistant E. coli and Shigella spp.: in vitro potential.BMC microbiology · 2026Article
- Phage Therapy as a Self-Replicating Strategy for Besieged Health Systems.Infection and drug resistance · 2026Review
- Phage Host Range Expansion Through Directed Evolution on Highly Phage-Resistant Strains ofInternational journal of molecular sciences · 2025Article
- Exploring urinary microbiome: insights into neurogenic bladder and improving management of urinary tract infections.Frontiers in cellular and infection microbiology · 2025Review
- Potential of an Isolated Bacteriophage to InactivateAntibiotics (Basel, Switzerland) · 2024Article
- The Potential Role of Persister Cells in Urinary Tract Infections.Current urology reports · 2023Review
- Co-Expression of Transcriptional Regulators and Housekeeping Genes inMicroorganisms · 2023Article
- Evaluation of the Lytic Activity of Various Phage Cocktails Against, ESBL-Producer, Non-Producer and Carbapenem-ResistantIndian journal of microbiology · 2023Article
- Bacteriophage-based techniques for elucidating the function of zebrafish gut microbiota.Applied microbiology and biotechnology · 2023Review
- Proof-of-Concept Standardized Approach Using a Single-Disk Method Analogous to Antibiotic Disk Diffusion Assays for Routine Phage Susceptibility Testing in Diagnostic Laboratories.Applied and environmental microbiology · 2022Article
- Two Newly IsolatedViruses · 2022Article
- Article
- A Novel Phage Cocktail Therapy of the Urinary Tract Infection in a Mouse Model.Archives of Razi Institute · 2021Article
- Natural Bred εAntibiotics (Basel, Switzerland) · 2021Article
- Interactions of Bacteriophages with Animal and Human Organisms-Safety Issues in the Light of Phage Therapy.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary tract infections (UTIs) are among the most prevalent microbial diseases and their financial burden on society is substantial. The continuing increase of antibiotic resistance worldwide is alarming so that well-tolerated, highly effective therapeutic alternatives are urgently needed.
objectiveTo investigate the effect of bacteriophages on Escherichia coli and Klebsiella pneumoniae strains isolated from the urine of patients suffering from UTIs. MATERIAL AND
methodsForty-one E. coli and 9 K. pneumoniae strains, isolated from the urine of patients suffering from UTIs, were tested in vitro for their susceptibility toward bacteriophages. The bacteriophages originated from either commercially available bacteriophage cocktails registered in Georgia or from the bacteriophage collection of the George Eliava Institute of Bacteriophage, Microbiology and Virology. In vitro screening of bacterial strains was performed by use of the spot-test method. The experiments were implemented three times by different groups of scientists.
resultsThe lytic activity of the commercial bacteriophage cocktails on the 41 E. coli strains varied between 66% (Pyo bacteriophage) and 93% (Enko bacteriophage). After bacteriophage adaptation of the Pyo bacteriophage cocktail, its lytic activity was increased from 66 to 93% and only one E. coli strain remained resistant. One bacteriophage of the Eliava collection could lyse all 9 K. pneumoniae strains.
conclusionsBased on the high lytic activity and the potential of resistance optimization by direct adaption of bacteriophages as reported in this study, and in view of the continuing increase of antibiotic resistance worldwide, bacteriophage therapy is a promising treatment option for UTIs highly warranting randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.